Market intelligence for the peptide supply chain
APIs ·

UAE tightens sourcing and traceability rules for peptide imports

November 16, 2026 · TideMetrix Brief
TideMetrix TakeNew UAE regulations place greater scrutiny on peptide suppliers, requiring verification of material origin, pharmaceutical quality and batch documentation. The measures could reshape sourcing arrangements for compounding pharmacies and their API suppliers.

The United Arab Emirates has introduced new controls on peptide imports, requiring stronger supplier verification, batch documentation and traceability for materials entering pharmaceutical compounding and research channels.

The Emirates Drug Establishment (EDE) issued Circular 46/2026 on November 5, with the requirements taking effect from the date of issuance.

The circular covers peptide materials intended for pharmaceutical compounding, clinical research and laboratory research. Finished peptide medicines with valid UAE marketing or emergency-use authorization are excluded and remain subject to existing regulatory requirements.

For pharmaceutical compounding, licensed medical warehouses must obtain prior EDE approval to import the covered pharmaceutical-grade peptides and may supply them only to licensed compounding pharmacies.

Importers must verify the identity and regulatory status of suppliers, establish the origin and pharmaceutical grade of materials, and obtain a certificate of analysis for each batch. Transport, storage and traceability through to the receiving facility must also be documented.

Approval is assessed individually according to the peptide substance, its source and pharmaceutical form. Inclusion in the circular's annex, or authorization in another country, does not automatically permit importation or compounding in the UAE.

The rules prohibit the use of research-grade or unknown-origin peptides in pharmaceutical compounding. Pharmacies must assess relevant quality attributes, including identity, concentration, impurities, degradation, aggregates and stability. Laboratory testing or a certificate of analysis alone does not establish that a product is safe, effective or authorized for human use.

Non-compliant materials must be quarantined immediately, and affected establishments are required to submit inventories within 30 days of the circular's issuance.

For peptide API manufacturers and distributors, the measures introduce explicit documentation and qualification obligations for the affected UAE market channels, without imposing a blanket restriction on authorized finished peptide medicines.

Sources

← Back to News